DEF 14A: 4D Molecular Therapeutics Sets Date for 2024 Annual Stockholders Meeting

4D Molecular Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 21, 2024, to vote on the election of a director and the ratification of the company's independent accounting firm.

Summary

• 4D Molecular Therapeutics will hold its 2024 Annual Meeting of Stockholders on May 21, 2024, at 1:00 p.m. Pacific time, as a virtual meeting.
• Stockholders of record as of April 3, 2024, are eligible to vote.
• The meeting will address the election of one Class I director for a term expiring in 2027 and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR the election of the director nominee and FOR the ratification of the accounting firm appointment.
• The company had 51,157,472 shares of common stock outstanding as of the record date.
• Stockholder proposals for the next annual meeting must be submitted by December 12, 2024, for inclusion in proxy materials, or between January 21, 2025, and February 20, 2025, for other proposals.
• The company's board consists of seven directors divided into three classes with staggered three-year terms.
• The board has determined that all directors, except for Dr. Kirn, are independent.
• The company has a Code of Business Conduct and Ethics applicable to all employees, officers, and directors.
• The company prohibits hedging transactions involving its equity securities by officers, directors, employees, and certain consultants.
• The company's Audit Committee has engaged PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm since 2016.
• The company's non-employee directors receive cash and equity compensation, with the Executive Chairperson receiving an annual retainer of $150,000.
• The company's executive officers include David Kirn (CEO), Uneek Mehra (CFO), Fariborz Kamal (President & COO), Robert Kim (CMO), and Scott Bizily (CLO).

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions, but does not express strong positive or negative sentiment.

Positives

• The company is providing a virtual meeting option to allow greater participation and improved communication for stockholders.
• The Board of Directors is actively engaged in risk oversight and has established committees to address specific areas of risk.
• The company has a Code of Business Conduct and Ethics and Corporate Governance Guidelines in place.
• The Audit Committee is recommending the selection of an independent registered public accounting firm.
• The company has change in control severance agreements with its NEOs.

Negatives

• Dr. Kirn is not considered an independent director due to his employment with the company.
• There were a few late filings for Section 16(a) reports.

Risks

• The document does not explicitly detail specific risks facing the company, but it mentions the Board's role in risk oversight and the establishment of committees to address risks inherent in their respective areas of oversight.
• The company is subject to the risk that the independent registered public accounting firm may not be ratified by stockholders.

Future Outlook

The document outlines the process and deadlines for stockholder proposals for the next annual meeting, providing a timeline for future corporate governance activities.

Management Comments

• The Board of Directors recommends voting FOR the election of the director nominee and FOR the ratification of the appointment of PricewaterhouseCoopers LLP.

Industry Context

As a publicly traded biopharmaceutical company, 4D Molecular Therapeutics' annual meeting and proxy statement are standard practices for corporate governance and transparency, aligning with industry norms.

Comparison to Industry Standards

• The company's director compensation program, including cash retainers and equity grants, is generally consistent with industry practices for similarly sized biopharmaceutical companies.
• The virtual format of the annual meeting reflects a growing trend among public companies to enhance accessibility and reduce costs.
• The company's corporate governance practices, such as having independent directors and key board committees, align with Nasdaq listing requirements and best practices.

Related Party Transactions

• In 2023, while our Chief Development Officer (CDO) was on leave, we engaged the services of Noriyuki Kasahara, M.D., Ph.D., a member of our Board of Directors, as interim CDO.
• Dr. Kasahara was paid $0.2 million in 2023 for his services as interim CDO.
• In March 2024, we entered into a research and option agreement with Reignite Therapeutics Inc. (Reignite), which such agreement covers research funding for vector discovery programs at Reignite and grants us an option to acquire such vectors and related intellectual property.
• David Kirn, M.D., our Chief Executive Officer, is President, Executive Chairman of the Board of Directors, and a controlling stockholder of Reignite.

Stakeholder Impact

• Shareholders are asked to vote on key proposals, influencing the company's direction.
• Employees are subject to the Code of Business Conduct and Ethics.
• Directors and executive officers are subject to specific compensation and governance policies.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce the voting results within four business days after the Annual Meeting via a Current Report on Form 8-K.
• The company will continue to engage with stockholders and address any questions or concerns they may have.

Key Dates

Keywords

proxy statement, annual meeting, directors, stockholders, corporate governance, executive compensation, PricewaterhouseCoopers, audit committee, 4D Molecular Therapeutics